



Ohio Administrative Code Rule 4731-16-17 Requirements for one-bite program.

Effective: January 31, 2019

(A) One-bite program is a confidential program for treatment of impaired practitioners of the medical board established pursuant to section 4731.251 of the Revised Code.

(B) Monitoring organization is an entity which conducts the one-bite program and performs monitoring services for impaired practitioners under a contract with the medical board.

(C) One-bite treatment provider is an entity approved by the board to provide evaluation and treatment to impaired practitioners participating in the one-bite program.

(D) Continuing care provider is an entity approved by the board to provide continuing care to impaired practitioners participating in the one-bite program pursuant to rule 4731-16-21 of the Administrative Code.

(E) Licensees of the board who may be impaired in the ability to practice in accordance with acceptable and prevailing standards of care and who want to participate in the one-bite program shall complete the following requirements:

(1) The licensee shall register with the monitoring organization under contract with the board and obtain a list of the one-bite program treatment providers approved by the board.

(2) If the licensee reports directly to an approved treatment provider, the licensee shall register with the monitoring organization upon referral from the approved treatment provider.

(3) The treatment provider shall conduct an evaluation in accordance with rule 4731-16-05 of the Administrative Code.

(4) The treatment provider shall provide the information regarding the diagnosis and eligibility determination to the monitoring organization for confirmation of eligibility.



(5) If the licensee is determined to be impaired and not to be eligible for the one-bite program, the licensee, the monitoring organization and the treatment provider shall report this information to the board.

(F) Once a licensee is determined to be impaired and eligible for the one-bite program, the licensee shall, within three days, report to an approved treatment provider for treatment. The treatment provider shall develop an individualized treatment plan that may include a combination of inpatient, residential, partial hospitalization and/or intensive outpatient treatment.

(1) The licensee shall be required to immediately suspend practice for a minimum of thirty days. The licensee shall suspend practice until the licensee is determined to be able to practice according to acceptable and prevailing standards by the treatment provider and the medical director of the monitoring organization.

(2) The treatment provider shall notify the board and monitoring organization of any licensee who returns to work prior to obtaining the release from the treatment provider and the monitoring organization medical director.

(3) The treatment provider shall notify the board and monitoring organization of any licensee who does not successfully complete the prescribed treatment.

(G) Within one week after successful completion of treatment, the monitoring organization shall ensure that the licensee has entered into an agreement with a board approved continuing care provider.

(1) The monitoring organization shall confirm that the licensee completes continuing care sessions at least one time per week for at least six months following the release from treatment.

(2) The licensee must continue the weekly continuing care meetings until released by the continuing care provider and the medical director of the monitoring organization.

(H) In order to continue participation in the one-bite program, after successful completion of



treatment, the licensee shall enter into an agreement with the monitoring organization for monitoring for at least five years. An individual who chooses not to continue in the one-bite program will be subject to the procedures in rule 4731-16-02 of the Administrative Code.

(1) The licensee shall be required to provide random, observed toxicology screenings of biological materials, including but not limited to, blood, urine, hair, saliva, breath, or fingernail samples for drugs and alcohol as directed by the monitoring organization with a minimum of two random, observed toxicology screenings per month.

(2) The licensee shall attend drug and alcohol support group meetings (e.g. alcoholics anonymous or narcotics anonymous) as directed by the monitoring organization with a minimum of attendance at ten meetings per month.

(3) The licensee shall be released from monitoring by the medical director of the monitoring organization upon successful completion of monitoring.

(I) Any relapse as defined in paragraph (B) of rule 4731-16-01 of the Administrative Code shall be reported to the board by the medical director of the monitoring organization and the licensee.

(J) The board shall develop guidelines in collaboration with the monitoring organization for the reporting of non-compliance with conditions of the one-bite program. Non-compliance shall be reported to the board by the licensee and the medical director of the monitoring organization.